New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control
Recruiting now
This study tests whether giving a special immune cell treatment (CAR-T therapy) followed by two additional drugs (mosunetuzumab and polatuzumab) can shrink tumors in people with aggressive non-Hodgkin lymphoma that has returned or not responded to prior treatments. About 22 adult…
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated May 14, 2026 12:06 UTC